

Robert Rieben
List of Publications, March 23, 2018**Peer Reviewed, Original Papers**

94. Abicht JM, Sfriso R, Reichart B, Längin M, Gahle K, Puga Yung GL, Seebach JD, **Rieben R**, Ayares D, Wold E, Klymiuk N, Baehr A, Kind A, Mayr T, Bauer A. Multiple genetically modified GTKO/hCD46/HLA-E/h β 2-mg porcine hearts are protected from complement activation and natural killer cell infiltration during ex vivo perfusion with human blood. *Xenotransplantation*. **2018**, e12390. DOI 10.1111/xen.12390.
93. Abdelhafez MM, Shaw J, Wilbs J, Despont A, **Rieben R**. Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures. *J Vis Exp* **2018**, (133), e56856.
92. Gygax E, Kaeser HU, Stalder M, Gahl B, **Rieben R**, Carrel T, Erdoes G. Type II Minimal-Invasive Extracorporeal Circuit for Aortic Valve Replacement: A Randomized Controlled Trial. *Artificial Organs* **2018**, 00(00):00–00. DOI 10.1111/aor.13093.
91. Zhang S, Shaw J, Banz Y, Bongoni AK, Taddeo A, Spirig R, Nolte MW, Cowan PJ, **Rieben R**. Effects of C1 inhibitor on endothelial cell activation in a rat hind limb ischemia/reperfusion injury model. *J Vasc Surg* 2017, S0741-5214(17)32653-8. DOI 10.1016/j.jvs.2017.10.072.
90. Puga Yung G, Bongoni A, Pradier A, Madelon N, Papaserafeim M, Sfriso R, Ayares D, Wolf E, Klymiuk N, Bähr A, Constantinescu M, Vögelin E, Kiermeir D, Jenni HJ, **Rieben R**, Seebach JD. Release of pig leukocytes and reduced human NK cell recruitment during ex vivo perfusion of HLA-E/human CD46 double-transgenic pig limbs with human blood. *Xenotransplantation* 2017, e12357. DOI 10.1111/xen.12357.
89. Sfriso R, Bongoni A, Banz Y, Klymiuk N, Wolf E, **Rieben R**. Assessment of the anticoagulant and anti-inflammatory properties of endothelial cells using 3D cell culture and non-anticoagulated whole blood. *J Vis Exp* 2017, 127:e56227. DOI 10.3791/56227.
88. Olariu R, Denoyelle J, Leclère FM, Dzhonova DV, Gajanayake T, Banz Y, Hayoz M, Constantinescu M, **Rieben R**, Vögelin E, Taddeo A. Intra-graft injection of tacrolimus promotes survival of vascularized composite allotransplantation. *J Surg Res* 2017, 218:49-57. DOI 10.1016/j.jss.2017.05.046.
87. Duisit, J, Maistriaux L, Taddeo A, Orlando G, Joris V, Coche E, Behets C, Lerut J, Dessy C, Cossu G, Vögelin E, **Rieben R**, Gianello P, Lengelé B. Bioengineering a human face graft. The matrix of identity. *Ann Surg* 2017 in press. DOI 10.1097/SLA.0000000000002396.
86. Bongoni AK, Salvaris E, Nordling S, Klymiuk N, Wolf E, Ayares DL, **Rieben R**, Magnusson PU, Cowan PJ. Surface modification of pig endothelial cells with a branched heparin conjugate improves their compatibility with human blood. *Scientific Reports* 2017, 7:4450. DOI 10.1038/s41598-017-04898-w.
85. Abdelhafez MM, Shaw J, Sutter D, Schnider J, Banz Y, Jenni HJ, Voegelin E, Constantinescu MA, **Rieben R**. Effect of C1-INH on ischemia/reperfusion injury in a porcine limb ex vivo perfusion model. *Molecular Immunology* 2017, 88:11-6124. DOI 10.1016/j.molimm.2017.06.021.

72. Bongoni AK, Kiermeir D, Denoyelle J, Jenni H, Burlak C, Seebach JD, Voegelin E, Constantinescu MA, **Rieben R**. Porcine extrahepatic vascular endothelial ASRG1 mediates platelet phagocytosis in vitro and in human-to-pig ex vivo xenoperfusion. *Transplantation* 2015, 99(4):693-701.
71. Gajanayake T, Olariu R, Leclère FM, Dhayani A, Yang Z, Bongoni AK, Banz Y, Constantinescu MA, Karp JM*, Vemula PK*, **Rieben R***, Vögelin E. A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft. *Sci Transl Med* 2014, 6:249ra110.
*co-corresponding authors
70. Bongoni AK, Kiermeir D, Jenni H, Bähr A, Ayares D, Klymiuk N, Wolf E, Voegelin E, Constantinescu MA, Seebach JD, **Rieben R**. Complement dependent early immunological responses during ex vivo xenoperfusion of hCD46/HLA-E double transgenic pig forelimbs with human blood. *Xenotransplantation* 2014, 21(3):230-243.
69. Dührkop C, **Rieben R**. Refinement of tourniquet-induced peripheral ischemia/reperfusion injury in rats: Comparison of 2h vs. 24h reperfusion. *Laboratory Animals* 2014, 48(2):143-154.
68. Dührkop C, Denoyelle J, Shaw S, **Rieben R**. Use of dextran sulfate in tourniquet-induced skeletal muscle reperfusion injury. *J Surg Res* 2014, 187(1):150-161.
67. Wunsch A, Bähr A, Bongoni AK, Kemter E, Blutke A, Baars W, Haertle S, Zakhartchenko V, Kurome M, Kessler B, Faber C, Reichart B, Wanke R, Schwinzer R, Nagashima H, **Rieben R**, Ayares D, Wolf E, Klymiuk N. Regulatory sequences of the porcine THBD gene facilitate endothelial-specific expression of bioactive human thrombomodulin in single- and multitransgenic pigs. *Transplantation* 2014, 97(2):138-147.
66. Schweizer DF, Schweizer R, Zhang S, Kamat P, Contaldo C, **Rieben R**, Eberli D, Giovanoli P, Erni D, Plock JA. Botulinum toxin A and B raise blood flow and increase survival of critically ischemic skin flaps. *J Surg Res* 2013, 184:1205–1213.
65. Bongoni AK, Kiermeir D, Jenni H, Wunsch A, Bähr A, Ayares D, Seebach JD, Wolf E, Klymiuk N, Constantinescu MA, Vögelin E, **Rieben R**. Activation of the Lectin Pathway of Complement in Pig-to-Human Xenotransplantation Models. *Transplantation* 2013, 96(9):791-799.
64. Khattab AA, Stieger S, Kamat PJ, Vandenberghe S, Bongoni A, Stone GW, Seiler C, Meier B, Hess OM, **Rieben R**. Effect of pressure-controlled intermittent coronary sinus occlusion (PICSO) on myocardial ischaemia and reperfusion in a closed-chest porcine model. *EuroIntervention* 2013, 9:398–406.
63. Barratt-Due A, Thorgersen EB, Egge K, Pischke S, Sokolov A, Hellerud BC, Lindstad JK, Pharo A, Bongoni AK, **Rieben R**, Nunn M, Scott H, Mollnes TE. Combined inhibition of complement C5 and CD14 markedly attenuates inflammation, thrombogenicity, and hemodynamic changes in porcine sepsis. *J Immunol* 2013, 191:819–827.
62. Bongoni AK, Lanz J, **Rieben R**, Banz Y. Development of a bead-based multiplex assay for the simultaneous detection of porcine inflammation markers using xMAP technology. *Cytometry A* 2013, 83:636–647.
61. Ruder TD, Ebert LC, Khattab AA, **Rieben R**, Thali MJ, Kamat P. Edema is a sign of early acute myocardial infarction on post-mortem magnetic resonance imaging. *Forensic Sci Med Pathol* 2013, 9(4):501-505.

60. Müller S, Constantinescu MA, Kiermeir DM, Gajanayake T, Bongoni AK, Vollbach FH, Meoli M, Plock J, Jenni H, Banic A, **Rieben R***, Vögelin E. Ischemia/reperfusion injury of porcine limbs after extracorporeal perfusion. *J Surg Res* 2013, 181:170–182.
*corresponding author
59. Leclère FMP, Lewbart GA, **Rieben R**, Vögelin E. Microsurgery and liver research: *Lumbricus terrestris*, a reliable animal model for training? *Clin Res Hepatol Gastroenterol* 2013, 37:166–170.
58. Duehrkop C, Banz Y, Spirig R, Miescher S, Nolte MW, Spycher M, Smith RAG, Sacks SH, **Rieben R**. C1 esterase inhibitor reduces lower extremity ischemia/reperfusion injury and associated lung damage. *PLoS ONE* 2013, 8:e72059.
57. Spirig R, Schaub A, Kropf A, Miescher S, Spycher MO, **Rieben R**. Reconstituted high-density lipoprotein modulates activation of human leukocytes. *PLoS One* 2013, 8(8), e71235.
56. Kamat P, Juon B, Jossen B, Gajanayake T, **Rieben R***, Vögelin E. Assessment of endothelium and inflammatory response at the onset of reperfusion injury in hand surgery. *J Inflamm (Lond)* 2012, 9:18-28.
*corresponding author
55. Veres-Nyeki KO, **Rieben R**, Spadavecchia C, Bergadano A. Pancuronium dose refinement in experimental pigs used in cardiovascular research. *Vet Anaest Analg* 2012, 39(5):529-532.
54. Banz Y, Hess OM, Meier P, Korchagina EY, Gordeeva EA, Robson SC, Gajanayake T, Csizmadia E, Mettler D, Haerberli A, Bovin NV, **Rieben R**. Evaluation of multimeric tyrosine-O-sulfate as a cytoprotectant in an in vivo model of acute myocardial infarction in pigs. *Cardiology* 2012, 121:59-70.
53. Jenni H, Rheinberger J, Czerny M, Gygax E, **Rieben R**, Krähenbühl E, Carrel T, Stalder M. Autotransfusion system or integrated automatic suction device in minimized extracorporeal circulation: influence on coagulation and inflammatory response. *Eur J Cardiothorac Surg* 2011, 39(5): e139-43.
52. Pochechueva T, Chinarev A, Spengler M, Korchagina E, Heinzelmann-Schwarz V, Bovin N, **Rieben R**. Multiplex suspension array for human anti-carbohydrate antibody profiling. *Analyst* 2011, 136:560-569.
51. Spirig R, Djafarzadeh S, Rgueira T, Shaw SG, von Garnier C, Takala J, Jakob SM, **Rieben R**, Lepper PM. Effects of TLR agonists on the hypoxia-regulated transcription factor HIF-1alpha and dendritic cell maturation under normoxic conditions. *PLoS One* 2010 5(6):e0010983. 2.81
50. Millard AL, Spirig R, Mueller NJ, Seebach JD, **Rieben R**. Inhibition of direct and indirect TLR-mediated activation of human NK cells by low molecular weight dextran sulfate. *Mol Immunol* 2010 47(14):2349-2358.
49. Constantinescu MA, Knall E, Xu X, Kiermeir DM, Jenni HJ, Gygax E, **Rieben R**, Banic A, Vögelin E. Preservation of amputated extremities by extracorporeal blood perfusion; a feasibility study in a porcine model. *J Surg Res* 2011, 171:291-299.
48. Spycher M, Matozan K, Minnig K, Zehnder R, Miescher S, Hoefflerer L, **Rieben R**. In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations. *Vox Sang* 2009 97(4):348-354.

47. Spirig R, Potapova I, Shaw-Boden J, Tsui J, **Rieben R**, Shaw SG. TLR2 and TLR4 agonists induce production of the vasoactive peptide endothelin-1 by human dendritic cells. *Mol Immunol* 2009 46(15):3178-3182.
46. Banz Y, Gajanayake T, Matozan K, Yang Z, **Rieben R**. Dextran sulfate modulates MAP kinase signaling and reduces endothelial injury in a rat aortic clamping model. *J Vasc Surg* 2009 50(1):161-170.
45. Gajanayake T, Sawitzki B, Matozan K, Korchagina EY, Lehmann M, Volk HD, **Rieben R**. Dextran Sulfate Facilitates Anti-CD4 mAb-Induced Long-Term Rat Cardiac Allograft Survival After Prolonged Cold Ischemia. *Am J Transplant* 2008 8(6):1151-1162.
44. Spirig R, van Kooten C, Obregon C, Nicod L, Daha MR, **Rieben R**. The Complement Inhibitor Low Molecular Weight Dextran Sulfate Prevents TLR4-Induced Phenotypic and Functional Maturation of Human Dendritic Cells. *J Immunol* 2008 181(2):878-890.
43. Banz Y, **Rieben R***, Zobrist C, Meier P, Shaw S, Lanz J, Carrel T, Berdat P. Addition of dextran sulfate to blood cardioplegia attenuates reperfusion injury in a porcine model of cardiopulmonary bypass. *Eur J Cardiothorac Surg* 2008 34(3):653-660.
*corresponding author
42. Stüssi G, Müller RJ, Passweg J, Schanz U, **Rieben R**, Seebach JD. ABO blood group incompatible haematopoietic stem cell transplantation and xenograft rejection. *Swiss Med Wkly* 2007 137(Suppl. 155):101S-108S.
41. Obukhova P, **Rieben R**, Bovin NV. Normal human serum contains high levels of anti Gal α 1-4GlcNAc antibodies. *Xenotransplantation* 2007 14(6): 627–635.
40. Banz Y, Hess OM, Robson SC, Csizmadia E, Mettler D, Meier P, Haeberli A, Shaw S, Smith RA, **Rieben R**. Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1. *Cardiovascular Research* 2007 76(3):482-493.
39. Tanner H, Mohacsi P, Fuller-Bicer GA, **Rieben R**, Meier B, Hess O, Hullin R. Cytokine activation and disease progression in patients with stable moderate chronic heart failure. *J Heart Lung Transplant* 2007 26(6):622-629.
38. Baumann BC, Stüssi G, Huggel K, Hawley RJ, **Rieben R**, and Seebach JD. Reactivity of human natural antibodies to endothelial cells from Gal alpha(1,3) Gal-deficient pigs. *Transplantation* 2007 83(2):193-201.
37. Banz Y, Hess OM, Robson SC, Mettler D, Meier P, Haeberli A, Csizmadia E, Korchagina EY, Bovin NV, **Rieben R**. Locally targeted cytoprotection with dextran sulfate attenuates experimental porcine myocardial ischemia/reperfusion injury. *Eur Heart J* 2005 26(21):2334-2343.
36. Stüssi G, Huggel K, Lutz HU, Schanz U, **Rieben R**, Seebach JD. Isotype-specific detection of ABO blood group antibodies using a novel, flow cytometric method. *Br J Haematol* 2005 130(6):954-963.
35. Banz Y, Cung T, Korchagina EY, Bovin NV, Haeberli Y, **Rieben R**. Endothelial cell protection and complement inhibition in xenotransplantation: a novel in vitro model using whole blood. *Xenotransplantation* 2005 12(6):434-443.

34. Baumann BC, Forte P, Hawley RJ, **Rieben R**, Schneider MKJ, Seebach JD. Lack of Gal α (1-3)Gal expression on porcine endothelial cells prevents complement-induced lysis but not direct xenogeneic NK cytotoxicity. *J Immunol* 2004 172(10):6460-6467.
33. Laumonier T, Walpen AJ, Matozan KM, Korchagina EY, Bovin NV, Haeberli A, Mohacsi PJ, **Rieben R**. Multimeric tyrosine sulfate acts as an endothelial cell protectant and prevents complement activation in xenotransplantation models. *Xenotransplantation* 2004 11(3):262-268.
32. Laumonier T, Mohacsi PJ, Matozan KM, Banz Y, Haeberli A, Korchagina EY, Bovin NV, Vanhove B, **Rieben R**. Endothelial Cell protection by dextran sulfate: A novel strategy to prevent acute vascular rejection in xenotransplantation. *Amer J Transpl* 2004 4(2):181-187.
31. Walpen A, Laumonier T, Aebi C, Mohacsi PJ, **Rieben R**. Immunoglobulin M-enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bactericidal activity of human serum. *Xenotransplantation* 2004 11(2):141-148.
30. Laumonier T, Walpen AJ, Maurus CF, Mohacsi PJ, Matozan KM, Korchagina EY, Bovin NV, Vanhove B, Seebach JD, **Rieben R**. Dextran sulfate acts as an endothelial cell protectant and inhibits human complement and natural killer cell-mediated cytotoxicity against porcine cells. *Transplantation* 2003 76(5):838-843.
29. Pochechueva TV, Ushakova NA, Preobrazhenskaya ME, Nifant'ev NE, Tsvetkov YE, Sablina MA, Tuzikov AB, Bird MI, **Rieben R**, Bovin NV. P-selectin blocking potency of multimeric tyrosine sulfates in vitro and in vivo. *Bioorg Med Chem Lett* 2003 13(10):1709-1712.
28. Tsvetkov DE, Cheshev, PE, Tuzikov AB, Chinarev AA, Pazynina GV, Sablina MA, Gambaryan AS, Bovin NV, **Rieben R**, Shashkov AS, Nifant'ev NE. Neoglycoconjugates based on dendrimers poly(aminoamides). *Russian Journal of Bioorganic Chemistry* 2002 28(6):470-486.
27. Pierson RN 3rd, Loyd JE, Goodwin A, Majors D, Dummer JS, Mohacsi P, Wheeler A, Bovin N, Miller GG, Olson S, Johnson J, **Rieben R**, Azimzadeh A. Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy. *Transplantation* 2002 74(1):79-84.
26. Roos A, **Rieben R**, Faber-Krol MC, Daha MR. IgM-enriched human intravenous immunoglobulin strongly inhibits complement-dependent porcine cell cytotoxicity mediated by human xenoreactive antibodies. *Xenotransplantation* 2003 10(6):596-605.
25. Caliezi C, Zeerleder S, Redondo M, Regli B, Rothen H-U, Zürcher-Zenklusen R, **Rieben R**, Devay J, Hack CE, Lämmle B, Wuillemin WA. C1-inhibitor in patients with severe sepsis or septic shock: beneficial effect on renal dysfunction. *Crit Care Med* 2002 30(8):1722-1728.7.05
24. Walpen AJ, Mohacsi PJ, Frey C, Roos A, Daha MR, **Rieben R**. Activation of complement pathways in xenotransplantation: an in vitro study. *Transplant Immunol* 2002 9(2-4):271-280.
23. Mohacsi P, **Rieben R**, Sigurdsson G, Tschanz HU, Schaffner T, Nydegger UE, Carrel T. Successful management of a B-type cardiac allograft into an O-type man with 31/2 year clinical follow-up. *Transplantation* 2001 72(7):1328-1330.
22. Basker M, Alwayn IPJ, Buhler L, Harper D, Abraham S, Kruger Gray H, Awwad M, Down J, **Rieben R**, White-Scharf ME, Sachs DH, Thall A, Cooper DKC. Clearance of mobilized porcine peripheral blood progenitor cells is delayed by depletion of the phagocytic reticuloendothelial system in baboons. *Transplantation* 2001 72(7):1278-1285.

21. Gerber B, Tinguely C, Bovin NV, **Rieben R**, Nydegger UE. Differences between synthetic oligosaccharide immunoabsorbents in depletion capacity for xenoreactive anti-Gal α 3Gal antibodies from human serum. *Xenotransplantation* 2001 8(2):106-114.
20. Fiorante P, Banz Y, Mohacsi PJ, Kappeler A, Wuillemin WA, Macchiarini P, Roos A, Daha MR, Schaffner T, Haerberli A, Mazmanian GM, **Rieben R**. Low molecular weight dextran sulfate prevents complement activation and delays hyperacute rejection in pig-to-human xenotransplantation models. *Xenotransplantation* 2001 8(1):24-35.
19. **Rieben R**, Bovin NV, Korchagina EY, Oriol R, Nifant'ev NE, Tsvetkov DE, Daha MR, Mohacsi PJ, Joziassse DH. Xenotransplantation: in vitro analysis of synthetic α galactosyl inhibitors of human anti-Gal α 3Gal antibodies. *Glycobiology* 2000 10(2):141-148.
18. Buonomano R, Tinguely C, **Rieben R**, Mohacsi PJ, Nydegger UE. Quantitation and characterization of anti-Gal α 3Gal antibodies in sera of 200 healthy persons. *Xenotransplantation* 1999 6(3):173-180.
17. Tsvetkov DE, Cheshev PE, Tuzikov AB, Pzynina GV, **Rieben R**, Bovin NV, Nifant'ev NE. Synthesis of neoglycoconjugate dendrimers. *Mendeleev Commun* 1999:47-50.
16. **Rieben R**, Roos A, Muizert Y, Tinguely C, Gerritsen AF, Daha MR. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. *Blood* 1999 93(3):942-951.
15. Macchiarini P, Oriol R, Azimzadeh A, de Montpreville V, **Rieben R**, Bovin N, Dartevelle P. Evidence of human non-alpha Gal antibodies involved in the hyperacute rejection of pig lungs and their removal by pig organ perfusion. *J Thorac Cardiovasc Surg* 1998 116(5):831-843.
14. Uetz-von Allmen E, Sturzenegger M, **Rieben R**, Rihs F, Frauenfelder A, Nydegger UE. Anti-ganglioside GM1 antibodies and their complement activating capacity in central and peripheral nervous system disorders and in controls. *Eur Neurol* 1998 39(2):103-110.
13. Macchiarini P, Mazmanian GM, Oriol R, de Montpreville V, Dulmet E, Fattal S, Libert JM, Dubin S, Nochy D, **Rieben R**, Dartevelle P. Ex-vivo lung model of pig-to-human hyperacute xenograft rejection. *J Thorac Cardiovasc Surg* 1997 114(3):315-325.
12. **Rieben R**, Korchagina EY, Bovin NV, Daha MR. Specificity of monoclonal antibodies against ABH- and related structures tested by ELISA with synthetic glycoconjugates. *Transf Clin Biolog* 1997 1:47-54.
11. Friedli F, **Rieben R**, Wegmüller E, Moerenhout M, Nydegger UE. Normal levels of allo- but increased levels of potentially autoreactive antibodies against ABO histo-blood group antigens in AIDS patients. *Clin Immunol Immunopathol* 1996 80(1):96-100.
10. **Rieben R**, Frauenfelder A, Nydegger UE. Spectrotype analysis of human ABO antibodies: evidence for different clonal heterogeneity of IgM, IgG, and IgA antibody populations. *Vox Sang* 1996; 70:104-111.
9. **Rieben R**, von Allmen E, Korchagina EY, Nydegger UE, Neethling, FA, Kujundzic M, Koren E, Bovin NV, Cooper DKC. Detection, immunoabsorption, and inhibition of cytotoxic activity of anti-alpha Gal antibodies using newly developed substances with synthetic Gal alpha1-3 Gal disaccharide epitopes. *Xenotransplantation* 1995;2:98-106.
8. **Rieben R**, Korchagina EY, von Allmen E, Kremer Hovinga J, Lämmle B, Jungi T, Bovin NV, Nydegger UE. In vitro evaluation of the efficacy and biocompatibility of new, synthetic ABO immunoabsorbents. *Transplantation* 1995;60(5):425-430.

7. von Allmen E, **Rieben R**, Nydegger UE. Development of a C1q-ABO-ELISA to measure C1 binding by human anti-A alloantibodies. *J Immunol Methods* 1994;171(1):85-92.2.10.
6. Auf der Maur C, Hodel M, Nydegger UE, **Rieben R**. Age-dependency of ABO histo-blood group antibodies - reexamination of an old dogma. *Transfusion* 1993;33(11):915-918.
5. **Rieben R**, Tucci M, Nydegger UE, Zubler RH. Self tolerance to human-A and human-B histo-blood group antigens exists at the B-cell level and cannot be broken by potent polyclonal B-cell activation in vitro. *Eur J Immunol* 1992;22(10):2713-2717.
4. **Rieben R**, Frauenfelder A, Nydegger UE. Naturally occurring ABO antibodies - long-term stable, individually distinct anti-A IgG spectrotypes. *Eur J Immunol* 1992;22(8):2129-2133.
3. Hasler CR, **Rieben R**, Buchs JP, Nydegger UE. Comparison between the levels of anti-A/B IgM/G antibodies in paired mother/child serum samples. *Transfus Sci* 1992;13(1):113-118.
2. **Rieben R**, Buchs JP, Flückiger E, Nydegger UE. Antibodies to histo-blood group substances A and B: agglutination titers, Ig class, and IgG subclasses in healthy persons of different age categories. *Transfusion* 1991;31(7):607-15.
1. **Rieben R**, Blaser K. Quantification of IgG and IgG4 antibodies to bee venom phospholipase A2 by competitive inhibition in ELISA. *J Immunol Methods* 1989;119(1):1-8.

Reviews, Book Sections, Case Reports, Letters, Editorials

25. Puga Yung G, **Rieben R**, Bühler L, Schuurman, HJ, Seebach JD. Xenotransplantation: where do we stand in 2016? *Swiss Medical Weekly* 2017, 147:w14403.
24. Cowan P, **Rieben R**. Modifying the Glycome in Pigs for Xenotransplantation. *Transplantation* 2016, 100(3):485-486.
23. Ahrens HE, Petersen B, Herrmann D, Schwinzer R, Rataj D, Tiede A, Winkler M, Ramakers W, Bongoni A, **Rieben R**, Niemann H. Experimental approaches towards overcoming the acute vascular rejection during pig-to-primate xenotransplantation. *Züchtungskunde* 2016, 88(1):32-51.
22. Duehrkop C, **Rieben R**. Ischemia/reperfusion injury: Effect of simultaneous inhibition of plasma cascade systems versus specific complement inhibition. *Biochem Pharmacol* 2014, 88(1):12–22.
21. Banz Y, **Rieben R**. Role of complement and perspectives for intervention in ischemia-reperfusion damage. *Annals of Medicine* 2012, 44(3):205-217.
20. Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, Ravetch JV, **Rieben R**. Intravenous immunoglobulins – understanding properties and mechanisms. *Clin Exp Immunol* 2009 158(Suppl 1):2-13.
19. Spirig R, Gajanayake T, Korsgren O, Nilsson B, **Rieben R**. Low molecular weight dextran sulfate as complement inhibitor and cytoprotectant in solid organ and islet transplantation. *Mol Immunol* 2008 45(16):4084-4094.
18. Banz Y, **Rieben R**. Exploring natural anticoagulation by endothelial cells: A novel in vitro model. *ALTEX* 2007 24(special issue):9-11.
17. Banz Y, **Rieben R**. Exploring the natural anticoagulation by endothelial cells: A novel in vitro model. *3R-Info-Bulletin* no. 34, January 2007.
16. Stüssi G, Müller RJ, Passweg J, Schanz U, **Rieben R**, Seebach JD. ABO blood group incompatible hematopoietic stem cell transplantation and xenograft rejection. *Swiss Med Wkly* 2007 137(1-2):13-20.
15. Banz Y, **Rieben R**. Endothelial cell protection in xenotransplantation: looking after a key player in rejection. *Xenotransplantation* 2006 13(1):19-30.
14. Nydegger UE, **Rieben R**. ABO-, nicht aber HLA-Gewebemerkmale schaffen es in die Tagespresse. *Schweiz Med Forum* 2005 5:1283–1284.
13. Nydegger UE, Tevæearai H, Berdat P, **Rieben R**, Carrel T, Mohacsi P, Flegel WA. Histo-blood group antigens as allo- and autoantigens. *Ann N Y Acad Sci* 2005 1050:40-51. 4.71.
12. **Rieben R**, Seebach JD. Xenograft rejection: IgG(1), complement and NK cells team up to activate and destroy the endothelium. *Trends Immunol* 2005 26(1):2-5.
11. Nydegger UE, **Rieben R**, Carrel T, Mohacsi P. Solid organ transplantation across the ABO histo-blood group barrier: a case report. *Transplant Proc.* 2004 36:1554-7.
10. Nydegger UE, **Rieben R**, Mohacsi PJ. Current precision of immunological extracorporeal plasma treatment. *Transfus Apheresis Sci* 2001 24(1):39-47.

9. **Rieben R.** Xenotransplantation – Beteiligungserfahrung Biotech, 4. EU-Forschungsrahmenprogramm. Euroscope-CH 2000 79:10-11.
8. **Rieben R.** Xenotransplantationsforschung in der Schweiz - Plädoyer für eine interdisziplinäre Zusammenarbeit. In: Potential and risk of xenotransplantation / Potential und Risiken der Xenotransplantation - Was Experten dazu meinen (Seebach JD, Candinas D, Largiader F, eds.) Luce Verlag, Murten 2000; pp. 158–163.
7. Nydegger UE, **Rieben R**, Lämmle B. Biocompatibility in transfusion medicine. Transfusion Sci 1996 17(4): 10-15.
6. Nydegger UE, **Rieben R**. Combined use of plasma exchange and intravenous immunoglobulins. Ann Med Int (Paris) 1994;145(5):287-292.
5. Zubler RH, Tucci A, **Rieben R**, Matthes T, Nydegger UE. Quantification of autoreactive lymphocytes in health and disease. In: Autoimmunity: Physiology and Disease (Cautinho A and Kazatchkine MD, eds.) Wiley-Liss Inc., New York 1994; pp. 173-190.
4. Nydegger UE, **Rieben R**, Kazatchkine MD. Intravenöse Immunglobulintherapie als Beeinflussungsmöglichkeit von autoimmunen Prozessen. In: Infektionen und Autoimmunerkrankungen II: Therapie mit Immunglobulinen und deren Derivaten (Salama A, Kurrle R eds.) Universitätsverlag Jena 1993; pp 15-27.
3. Nydegger U, **Rieben R**. Nouveaux aspects immunologiques et cliniques des groupes sanguins ABO. Médecine et Hygiène 1992;50:1334-1337.
2. Nydegger UE, **Rieben R**, Aeschbacher B. Biocompatibility of apheresis harness. Transfus Sci 1990;11(1):43-54.
1. Nydegger UE, **Rieben R**, Jungi TW. Synergy between plasma exchange and intravenous immunoglobulin. In: Nydegger UE, ed. Therapeutic Hemapheresis in the 1990's. Basel: Karger, 1990: 31-50. (Hässig A, Lundsgaard-Hansen P, eds. Current Studies in Hematology and Blood Transfusion; Vol 57).